MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Prothena Corp PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

6.39 -2.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.25

Max

6.53

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.2M

-60M

Pardavimai

705K

2.8M

Pelno marža

-2,128.536

Darbuotojai

163

EBITDA

-682K

-65M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+233.94% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-400M

346M

Ankstesnė atidarymo kaina

8.98

Ankstesnė uždarymo kaina

6.39

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Prothena Corp PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-11 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FCC Approves U.S. Cellular Sale to T-Mobile

2025-07-11 17:28; UTC

Pagrindinės rinkos jėgos

SharpLink Gaming Gains on Ethereum Purchase

2025-07-11 16:57; UTC

Uždarbis

BASF Cuts Outlook on Global Economy Uncertainty

2025-07-11 21:45; UTC

Rinkos pokalbiai

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025-07-11 19:46; UTC

Įsigijimai, susijungimai, perėmimai

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025-07-11 19:45; UTC

Rinkos pokalbiai

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025-07-11 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025-07-11 18:18; UTC

Rinkos pokalbiai

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025-07-11 17:35; UTC

Rinkos pokalbiai

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025-07-11 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025-07-11 16:53; UTC

Rinkos pokalbiai

Crude Futures Add to Early Gains -- Market Talk

2025-07-11 16:42; UTC

Uždarbis

BASF Cuts Outlook on Global Economic Uncertainty

2025-07-11 16:08; UTC

Rinkos pokalbiai

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025-07-11 16:05; UTC

Uždarbis

BASF Will Publish Half-Year Results on July 30

2025-07-11 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-11 16:04; UTC

Rinkos pokalbiai

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025-07-11 16:03; UTC

Uždarbis

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025-07-11 16:02; UTC

Uždarbis

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025-07-11 16:01; UTC

Uždarbis

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025-07-11 16:00; UTC

Uždarbis

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025-07-11 15:59; UTC

Uždarbis

BASF Cuts 2025 Earnings View

2025-07-11 15:58; UTC

Uždarbis

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025-07-11 15:57; UTC

Uždarbis

BASF 2Q EBIT Before Special Items EUR810M

2025-07-11 15:54; UTC

Uždarbis

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

2025-07-11 15:54; UTC

Uždarbis

BASF 2Q Sales Fell 2.1% on Year

2025-07-11 15:53; UTC

Uždarbis

BASF 2Q Sales EUR15.77B

2025-07-11 15:52; UTC

Uždarbis

BASF: This Was in Line With Consensus Estimates

2025-07-11 15:52; UTC

Uždarbis

BASF 2Q Ebitda Before Special Items EUR1.77B

2025-07-11 15:49; UTC

Uždarbis

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

2025-07-11 15:41; UTC

Rinkos pokalbiai

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Akcijų palyginimas

Kainos pokytis

Prothena Corp PLC Prognozė

Kainos tikslas

By TipRanks

233.94% į viršų

12 mėnesių prognozė

Vidutinis 21.94 USD  233.94%

Aukščiausias 81 USD

Žemiausias 4 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Prothena Corp PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

4

Pirkti

5

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 7.35Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.